Latest news
Should FDA Approval of ORZEYFUL for Narcolepsy Type 1 Prompt Action From Takeda Pharmaceutical (TSE:4502) Investors? - simplywall.stsimplywall.st · Sat, 08 Aug 2026 11:46:03 GMTFDA approves Orzeyful, first drug to treat all symptoms of narcolepsy type 1 - managedhealthcareexecutive.commanagedhealthcareexecutive.com · Fri, 07 Aug 2026 20:06:51 GMTFDA approves first-in-class drug to treat narcolepsy - Drug Discovery NewsDrug Discovery News · Fri, 07 Aug 2026 19:48:16 GMTFDA approves Takeda’s first-in-class narcolepsy drug - EMJEMJ · Fri, 07 Aug 2026 15:12:52 GMTFDA approves Orzeyful for narcolepsy type 1 in adults - American Academy of Sleep Medicine | AASMAmerican Academy of Sleep Medicine | AASM · Fri, 07 Aug 2026 14:23:12 GMTFierce Pharma Asia—Takeda’s historic narcolepsy nod; Daiichi’s accounting error; Astellas’ revenue beat - Fierce PharmaFierce Pharma · Fri, 07 Aug 2026 12:35:10 GMTFDA Approves First Narcolepsy Drug That Targets the Brain Signal Loss Behind the Disorder - Medical DailyMedical Daily · Fri, 07 Aug 2026 10:30:02 GMTTakeda nets first-in-class advantage on narcolepsy drug’s FDA go-ahead - Pharmaceutical TechnologyPharmaceutical Technology · Fri, 07 Aug 2026 09:53:37 GMT